Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Arcturus Therapeutics Holdings Inc (ARCT) USD0.001

Sell:$45.21 Buy:$45.49 Change: $3.29 (6.10%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $3.29 (6.10%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $3.29 (6.10%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Arcturus Therapeutics Holdings Inc. is a clinical-stage messenger ribonucleic acid (mRNA) medicines and vaccines company. The Company’s technologies include LUNAR lipid-mediated delivery, STARR mRNA Technology and mRNA drug substance along with drug product manufacturing. Its pipeline of ribonucleic acid (RNA) therapeutic candidates include programs to treat ornithine transcarbamylase (OTC) deficiency, cystic fibrosis, glycogen storage disease type three, hepatitis B, non-alcoholic steatohepatitis (NASH) and a self-replicating mRNA vaccine for severe acute respiratory syndrome coronavirus two (SARS-CoV-2). Its RNA therapeutics platforms have applications in types of nucleic acid medicines, including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, deoxyribonucleic acid (DNA) and gene editing therapeutics. The Company is focused on liver and respiratory diseases.

Contact details

10628 Science Center Dr Ste 250
United States
+1 (858) 9002660

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$1.42 billion
Shares in issue:
26.28 million
United States
US dollar

Key personnel

  • Peter Farrell
    Independent Chairman of the Board
  • Joseph Payne
    President, Chief Executive Officer, Director
  • Andrew Sassine
    Chief Financial Officer, Director
  • Padmanabh Chivukula
    Chief Operating Officer, Chief Scientific Officer
  • Steven Hughes
    Chief Development Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.